Stock A321550 TIUMBIO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News TiumBio Co., Ltd.

Equities

A321550

KR7321550006

End-of-day quote Korea S.E.
Other stock markets
 23:00:00 27/05/2024 BST 		5-day change 1st Jan Change
6,880 KRW -0.15% Intraday chart for TiumBio Co., Ltd. -2.82% -29.58%
05-08 TiumBio Co., Ltd. Announces Positive Topline Data from Phase 2A Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain CI
03-26 Tiumbio Co., Ltd. Submits CTA for Phase 1B Clinical Trial of TU7710, A Long-Acting Recombinant Activated Factor VII, in Hemophilia A or B Patients CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TiumBio Co., Ltd. Announces Positive Topline Data from Phase 2A Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain
CI
Tiumbio Co., Ltd. Submits CTA for Phase 1B Clinical Trial of TU7710, A Long-Acting Recombinant Activated Factor VII, in Hemophilia A or B Patients
CI
TiumBio Co., Ltd. Announces to Initiate Phase 2 Trial of TU2218 for Cancer
CI
TiumBio Co., Ltd. announced that it has received KRW 19.9999947 billion in funding from SK Chemicals Co.,Ltd
CI
TiumBio Co., Ltd. announced that it expects to receive funding from SK Chemicals Co.,Ltd
CI
TiumBio Co., Ltd. announced that it has received KRW 18.5 billion in funding from a group of investors
CI
TiumBio Co., Ltd.(KOSDAQ:A321550) dropped from S&P Global BMI Index
CI
TiumBio Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Hansoh Pharmaceutical Group Company Limited Announces Licensing Agreement with Tiumbio Co., Ltd
CI
Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates
CI
Protium Science announced that it has received KRW 6 billion in funding from TiumBio Co., Ltd.
CI
Protium Science announced that it expects to receive KRW 6 billion in funding from TiumBio Co., Ltd.
CI
TiumBio Co., Ltd. announced that it has received KRW 49.99982815 billion in funding from Hanyang Securities Co. Ltd., EBEST Investment & Securities Co., Ltd. and other investors
CI
TiumBio Co., Ltd. announced that it has received KRW 25 billion in funding
CI
TiumBio Co., Ltd. announced that it expects to receive KRW 49.99982815 billion in funding from Hanyang Securities Co. Ltd., EBEST Investment & Securities Co., Ltd. and other investors
CI
SK Plasma Co., Ltd. announced that it expects to receive KRW 110.00001 billion in funding from SK Discovery Co., Ltd., TiumBio Co., Ltd., and another investor
CI
TiumBio Co., Ltd.(KOSDAQ:A321550) added to S&P Global BMI Index
CI
TiumBio Co. Ltd. has completed an IPO in the amount of KRW 30 billion.
CI
TiumBio Co. Ltd. has filed an IPO.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A321550 Stock
  4. News TiumBio Co., Ltd.